The invention relates to modulating the SIRP±-CD47 interaction in order to treat haematological cancer and compounds therefor. In some embodiments, there is provided methods and uses of SIRP± polypeptides, fragments and fusion proteins for treating haematological cancer, preferably human acute myeloid leukemia.